HUP0301787A2 - A sertralin késleltetett kibocsátású dózisformái - Google Patents

A sertralin késleltetett kibocsátású dózisformái

Info

Publication number
HUP0301787A2
HUP0301787A2 HU0301787A HUP0301787A HUP0301787A2 HU P0301787 A2 HUP0301787 A2 HU P0301787A2 HU 0301787 A HU0301787 A HU 0301787A HU P0301787 A HUP0301787 A HU P0301787A HU P0301787 A2 HUP0301787 A2 HU P0301787A2
Authority
HU
Hungary
Prior art keywords
dosage forms
delayed
sertraline
release dosage
forms
Prior art date
Application number
HU0301787A
Other languages
English (en)
Inventor
William John Curatolo
Hylar Lewis Friedman
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0301787(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0301787A2 publication Critical patent/HUP0301787A2/hu
Publication of HUP0301787A3 publication Critical patent/HUP0301787A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A jelen találmány olyan késleltetet kibocsátású sertralindózisformákról gondoskodik, amelyek a Tmax értéket és amellékhatásokat csökkentik. A dózisformák általában agasztrointesztinális rendszerben helyzetükre érzékeny térbelilegkésleltetett formák, vagy egy előre beállított periódus alapjánidőlegesen késleltetett formák, utóbbi esetben a gasztrointesztinálisrendszerben elfoglalt helyzetüktől függetlenek. Az ilyen dózisformákazonosítására szolgáló in vitro teszteket is bemutatják. Ó
HU0301787A 1997-07-01 1998-06-16 Delayed-release dosage forms of sertraline HUP0301787A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5149997P 1997-07-01 1997-07-01
PCT/IB1998/000937 WO1999001122A1 (en) 1997-07-01 1998-06-16 Delayed-release dosage forms of sertraline

Publications (2)

Publication Number Publication Date
HUP0301787A2 true HUP0301787A2 (hu) 2003-11-28
HUP0301787A3 HUP0301787A3 (en) 2005-04-28

Family

ID=21971681

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301787A HUP0301787A3 (en) 1997-07-01 1998-06-16 Delayed-release dosage forms of sertraline

Country Status (41)

Country Link
EP (1) EP1007024B1 (hu)
JP (1) JP3786715B2 (hu)
KR (1) KR100369698B1 (hu)
CN (4) CN1494899A (hu)
AP (1) AP1199A (hu)
AR (1) AR038394A2 (hu)
AT (1) ATE245415T1 (hu)
AU (1) AU727152B2 (hu)
BG (1) BG64742B1 (hu)
BR (1) BR9809895A (hu)
CA (1) CA2290969C (hu)
DE (1) DE69816624T2 (hu)
DK (1) DK1007024T3 (hu)
DZ (1) DZ2547A1 (hu)
EA (1) EA001906B1 (hu)
ES (1) ES2202858T3 (hu)
GT (1) GT199800091A (hu)
HK (1) HK1027982A1 (hu)
HN (1) HN1998000099A (hu)
HR (1) HRP980376B1 (hu)
HU (1) HUP0301787A3 (hu)
ID (1) ID23187A (hu)
IL (2) IL133081A (hu)
IS (1) IS5267A (hu)
MA (1) MA24585A1 (hu)
NO (1) NO996519L (hu)
NZ (1) NZ501249A (hu)
OA (1) OA11247A (hu)
PA (1) PA8454201A1 (hu)
PE (1) PE84399A1 (hu)
PL (1) PL337799A1 (hu)
PT (1) PT1007024E (hu)
SI (1) SI1007024T1 (hu)
SK (1) SK173299A3 (hu)
TN (1) TNSN98122A1 (hu)
TR (1) TR199903295T2 (hu)
TW (1) TW575437B (hu)
UA (1) UA63953C2 (hu)
UY (1) UY25068A1 (hu)
WO (1) WO1999001122A1 (hu)
ZA (1) ZA985710B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653839A1 (en) 1998-11-02 2000-05-11 John G. Devane Multiparticulate modified release composition
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
AU782059B2 (en) * 1999-05-20 2005-06-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
BR0014166A (pt) 1999-09-03 2002-05-14 Lilly Co Eli Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001058429A1 (en) * 2000-02-10 2001-08-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
ATE526951T1 (de) * 2001-04-10 2011-10-15 Sun Pharma Advanced Res Co Ltd Zubereitung zur getakteten freisetzung
WO2003013480A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CN108014087A (zh) * 2017-12-27 2018-05-11 江苏联环药业股份有限公司 一种盐酸舍曲林胶囊的制备方法
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法
CN114129540B (zh) * 2021-11-19 2022-07-05 浙江维康药业股份有限公司 一种肝苏胶囊及其制作方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
EP0357364B1 (en) * 1988-08-30 1993-07-28 E.I. Du Pont De Nemours And Company A process for flash-spinning dry polymeric plexifilamentary film-fibril strands
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
TR199903295T2 (xx) 2000-08-21
PL337799A1 (en) 2000-09-11
OA11247A (en) 2002-11-19
MA24585A1 (fr) 1998-12-31
HRP980376B1 (en) 2002-12-31
SK173299A3 (en) 2000-11-07
GT199800091A (es) 1999-12-21
IL152304A0 (en) 2003-05-29
HRP980376A2 (en) 1999-04-30
DE69816624D1 (de) 2003-08-28
ZA985710B (en) 2000-01-10
PE84399A1 (es) 1999-09-11
DK1007024T3 (da) 2003-11-17
TNSN98122A1 (fr) 2005-03-15
CN1261273A (zh) 2000-07-26
CA2290969C (en) 2004-02-17
UA63953C2 (uk) 2004-02-16
SI1007024T1 (en) 2003-12-31
UY25068A1 (es) 2000-12-29
AU7545198A (en) 1999-01-25
ATE245415T1 (de) 2003-08-15
DE69816624T2 (de) 2004-02-19
AU727152B2 (en) 2000-12-07
EP1007024B1 (en) 2003-07-23
WO1999001122A1 (en) 1999-01-14
IS5267A (is) 1999-11-23
CN1494899A (zh) 2004-05-12
AR038394A2 (es) 2005-01-12
KR100369698B1 (ko) 2003-01-30
KR20010013522A (ko) 2001-02-26
HK1027982A1 (en) 2001-02-02
IL133081A0 (en) 2001-03-19
JP2000513751A (ja) 2000-10-17
HUP0301787A3 (en) 2005-04-28
ID23187A (id) 2000-03-23
ES2202858T3 (es) 2004-04-01
AP9801278A0 (en) 1998-06-30
NZ501249A (en) 2001-06-29
AP1199A (en) 2003-08-28
CA2290969A1 (en) 1999-01-14
NO996519D0 (no) 1999-12-28
JP3786715B2 (ja) 2006-06-14
BG64742B1 (bg) 2006-02-28
CN1151783C (zh) 2004-06-02
CN1475208A (zh) 2004-02-18
BG103916A (en) 2000-07-31
DZ2547A1 (fr) 2003-02-08
NO996519L (no) 2000-02-29
PA8454201A1 (es) 2000-09-29
HN1998000099A (es) 1998-10-22
TW575437B (en) 2004-02-11
EP1007024A1 (en) 2000-06-14
CN1475209A (zh) 2004-02-18
PT1007024E (pt) 2003-11-28
EA199900965A1 (ru) 2000-08-28
IL133081A (en) 2005-09-25
EA001906B1 (ru) 2001-10-22
BR9809895A (pt) 2000-08-01

Similar Documents

Publication Publication Date Title
HUP0301787A2 (hu) A sertralin késleltetett kibocsátású dózisformái
DK0975333T3 (da) Alginatgel med langvarig frigörelse
HUP0202512A2 (hu) Fehérjék polimerizációját gátló anyagok és eljárások ezek alkalmazására
NO20005564L (no) Biodegraderbare alginatgeler med langvarig frigjörelse
BR9600893A (pt) Polioxaésteres alifáticos dispositivos e matriz de liberação de droga
TR199701018T1 (xx) Oral 2-metil-tieno-benzodiazepin form�lasyonu.
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
HUP0300814A2 (hu) Peptidszelekciós módszer
HUP0001748A2 (hu) Transzdermális eszköz tesztoszteron felszabadítására
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
HUP0103883A2 (hu) Új, késleltetett felszabadulású, orális készítmények
NO996518D0 (no) Sertralinsalter og doseringsformer av sertralin med vedvarende frigjoering
HUP0003982A1 (hu) Renin-angiotenzin inhibitorok alkalmazása, hipoxia vagy gyengült metabolikus funkció kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0104131A2 (hu) Aminnal reakcióra képes egy vagy több aktív összetevőt tartalmazó készítmények
DK0878463T3 (da) Excitatoriske aminosyrereceptormodulatorer
HUP0300246A2 (en) Delivery system
DE69734071D1 (de) Anzeige des erfolgten gebrauchs bei einweg-stethoskopen
HUP0001917A2 (hu) Sclerosis multiplex kezelése kopolimer-1 bevételével vagy inhalálásával
YU58599A (sh) Gelovi sa usporenim podržanim oslobađanjem
ATE226592T1 (de) Peptide, die metallproteinasen und die tnf- freisetzung hemmen, und ihre therapeutische verwendung
HUP0002719A2 (hu) Hatásos komponensként ace (angiotenzin-konvertáz enzim)-gátló anyagot tartalmazó, szabályozott felszabadulást biztosító gyógyászati készítmény
ES2075942T3 (es) Sistema matricial autoadhesivo para la liberacion prolongada de pirebidil.
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
HUP0004605A1 (hu) Presenilinek és a béta-amiloid peptid vagy prekurzora közötti kölcsönhatás gátlására képes peptidek
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions